Legislators
Bills
Statements
Lobbying
Travel
Searching...- Lobbying
- Lobbying by Sanofi-aventis U.S., Inc.
Lobbying Relationship
Bills mentioned
H.R.3590: Patient Protection and Affordable Care Act
Sponsor: Charles B. Rangel (D-N.Y.)
H.R.3962: Preservation of Access to Care for Medicare Beneficiaries and Pension...
Sponsor: John D. Dingell (D-Mich.)
H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act
Sponsor: Henry A. Waxman (D-Calif.)
H.R.1548: Pathway for Biosimilars Act
Sponsor: Anna G. Eshoo (D-Calif.)
H.R.3200: America's Affordable Health Choices Act of 2009
Sponsor: John D. Dingell (D-Mich.)
H.R.759: Food and Drug Administration Globalization Act of 2009
Sponsor: John D. Dingell (D-Mich.)
S.1082: Food and Drug Administration Revitalization Act
Sponsor: Edward M. Kennedy (D-Mass.)
H.R.2900: Food and Drug Administration Amendments Act of 2007
Sponsor: John D. Dingell (D-Mich.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
| Lobbyist | Covered positions? |
|---|---|
| Paul Kim | n/a |
| Nick Littefield | n/a |
| David Mohler | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate